NDAORALTABLETPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
QULIPTA (atogepant) by AbbVie is calcitonin gene-related peptide receptor antagonists [moa]. Approved for episodic migraine, chronic migraine, migraine. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QULIPTA (atogepant) is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved by the FDA on September 28, 2021. It is indicated for migraine prevention in adults. The drug works by blocking CGRP receptors in the central and peripheral nervous system, reducing migraine frequency and severity. QULIPTA represents a novel oral alternative to injectable CGRP monoclonal antibodies in the preventive migraine treatment landscape.
$0.1BPart D
16.8 years to LOEMechanism of Action
Calcitonin Gene-related Peptide Receptor Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Receptor Antagonist
Indications (3)
Worked on QULIPTA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.